Approved indications: Cangrelor is approved as a short-term intravenous antiplatelet agent used during percutaneous coronary intervention (PCI) in adults who have not received an oral P2Y12 inhibitor and are not being treated with a glycoprotein IIb/IIIa inhibitor, to lower the risk of periprocedural heart attack, repeat revascularization, and stent thrombosis.

Common off-label uses: Clinicians may use cangrelor off-label as a temporary "bridge" in high-risk patients who must interrupt oral P2Y12 inhibitors before or after surgery or who cannot take medicines by mouth; evidence comes mainly from small clinical studies and observational data, so these uses are guided by specialist judgment rather than formal FDA approval.

Efficacy expectations:

• Platelet inhibition begins within a few minutes of the bolus and infusion, providing rapid protection during PCI.
• Clinical trials have shown cangrelor reduces periprocedural ischemic events (especially myocardial infarction and stent thrombosis) compared with clopidogrel started in the cath lab.
• Because its effect reverses within about an hour of stopping the infusion, bleeding risk declines quickly once treatment ends, in contrast to oral P2Y12 inhibitors whose effects last for days.
• It is not used for long-term prevention after PCI; an oral P2Y12 inhibitor is started around the time the infusion is discontinued to maintain ongoing protection.

Typical dosing and route: In adults undergoing PCI, cangrelor is given only by intravenous route as a 30 microgram/kg bolus immediately before the procedure, followed by a continuous infusion of 4 microgram/kg/min for at least 2 hours or for as long as the PCI lasts, whichever is longer.

Age and organ function considerations: Dosing is weight-based and does not usually require adjustment for older age or for renal or hepatic impairment, because the drug is rapidly inactivated in the bloodstream rather than relying on kidney or liver metabolism.

How it is administered:

• The infusion is prepared and given by healthcare professionals through a dedicated IV line in the catheterization laboratory or intensive-care setting.
• It does not depend on meals or time of day, as it is used only around the time of the PCI procedure.
• An oral P2Y12 inhibitor (such as clopidogrel, prasugrel, or ticagrelor) is started during or immediately after the infusion is stopped to maintain platelet inhibition after cangrelor is discontinued, following specific timing recommendations for each oral drug.

Special dosing instructions:

• The bolus must be given in full before or at the start of PCI, and the infusion should not be interrupted unless clinically necessary.
• No patient self-dosing is involved; all adjustments are made by the procedural team based on the course of the intervention and bleeding risk.

Missed dose or interruption: Because cangrelor is given only in monitored settings as a continuous infusion, issues such as missed doses are managed by healthcare staff; if the infusion is stopped early, platelet function typically returns toward normal within about an hour, and the team decides whether to restart the infusion or rely on an oral P2Y12 agent.

Overdose: An overdose would mainly increase bleeding risk; management consists of stopping the infusion, applying local measures, providing supportive care (and transfusion if needed), and monitoring, with the expectation that the antiplatelet effect will decline rapidly once the drug is discontinued, as there is no specific reversal agent.

Common side effects:

• The most frequent adverse effect is bleeding, often at the catheter insertion site, from the gums or nose, or as easy bruising; these events are usually mild to moderate but can occasionally be serious.
• Other reported symptoms include headache, back or abdominal discomfort, and minor drops in hemoglobin related to blood loss.
• Because the drug acts and clears quickly, minor bleeding often improves after the infusion is stopped, but all bleeding during therapy is taken seriously and monitored closely.

Serious or rare adverse effects:

• Major bleeding (such as gastrointestinal bleeding, large hematomas, or, rarely, intracranial hemorrhage) can occur and may require transfusion or urgent intervention.
• Allergic or hypersensitivity reactions, including rash, hives, or swelling of the face, lips, or throat, and very rarely anaphylaxis, require immediate medical attention.
• Any sudden shortness of breath, chest tightness, or hemodynamic instability during infusion is treated as an emergency.

Warnings and precautions:

• Cangrelor is contraindicated in patients with significant active bleeding or known serious hypersensitivity to cangrelor or its components.
• Use requires particular caution in people with a history of major bleeding, recent surgery, uncontrolled high blood pressure, or those receiving additional blood thinners (such as heparin, low molecular weight heparin, direct oral anticoagulants, or GP IIb/IIIa inhibitors).
• Pregnancy and breastfeeding: human data are limited; animal studies have not shown major birth defects, and exposure to a breastfed infant is expected to be low because of the very short half-life, so use is generally reserved for situations where the potential maternal benefit clearly outweighs potential risk.
• Older adults, and patients with kidney or liver impairment, do not usually require dose adjustment, but they may have a higher baseline risk of bleeding and are monitored closely.

Comparative safety: During PCI, overall bleeding rates with cangrelor are similar to or somewhat higher than with clopidogrel, but its very rapid offset means that stopping the infusion can quickly reduce ongoing antiplatelet effect if bleeding occurs.

Reporting side effects and safety updates: Patients or caregivers should promptly inform the treating healthcare team about any signs of bleeding or other unexpected symptoms during or after the infusion, and side effects can be reported through the FDA’s MedWatch reporting system or the manufacturer’s drug safety line for up-to-date safety information.

Prescription and over-the-counter drugs:

• Combining cangrelor with other antiplatelet or anticoagulant drugs (such as aspirin, heparin, low molecular weight heparin, bivalirudin, warfarin, or direct oral anticoagulants) increases the risk of bleeding, so such combinations are used only when clearly indicated and under close monitoring.
• Clopidogrel and prasugrel should not be administered during a cangrelor infusion because cangrelor blocks their active metabolites from binding to the P2Y12 receptor; these drugs are instead loaded immediately after the infusion is stopped.
• Ticagrelor’s activity is not significantly attenuated by cangrelor and can be given during or immediately after the infusion according to recommended protocols.
• Cangrelor is not metabolized by cytochrome P450 enzymes, so it has few classic drug–drug interactions via liver enzyme pathways.

Supplements, herbal products, and alcohol:

• Products that affect clotting—such as high-dose aspirin or NSAIDs, fish oil, ginkgo, garlic, or ginseng—may further increase bleeding risk when used in patients receiving multiple antithrombotic agents.
• Alcohol has no specific interaction with cangrelor itself, but heavy drinking can raise the risk of gastrointestinal bleeding and is generally discouraged in people on other blood thinners.

Food and diagnostic/imaging procedures:

• There are no important food interactions because cangrelor is given intravenously, not absorbed from the gut.
• Its very short half-life allows clinicians to stop the infusion shortly before surgery or invasive procedures to reduce bleeding risk, with no known direct interference with imaging contrast agents or most diagnostic tests.

Precautions and monitoring:

• Use with caution in patients with conditions that predispose to bleeding (recent major surgery, active peptic ulcer disease, severe uncontrolled hypertension, prior hemorrhagic stroke) and in those receiving multiple anticoagulant or antiplatelet drugs.
• During therapy, the medical team monitors for signs of bleeding (access-site hematomas, drops in hemoglobin/hematocrit, blood in stool or urine), vital signs, and, when appropriate, platelet counts and other labs.
• Because the drug is given for a short duration in highly monitored settings, routine outpatient blood tests specifically for cangrelor are not usually required.

Q: What is cangrelor used for?
A: Cangrelor is an intravenous antiplatelet medicine used during percutaneous coronary intervention (such as coronary stent placement) in adults who are not already on an oral P2Y12 inhibitor, to lower the risk of procedure-related heart attack and stent clotting.

Q: How quickly does cangrelor start working and how long do its effects last?
A: It begins to inhibit platelets within minutes of the initial bolus and infusion, and its effects usually wear off about an hour after the infusion is stopped, so normal clotting function returns relatively quickly.

Q: Why do I need an oral blood thinner if I received cangrelor?
A: Cangrelor is meant only for short-term use during the procedure, so an oral P2Y12 inhibitor like clopidogrel, prasugrel, or ticagrelor is started during or just after the infusion to provide longer-term protection against clots in the treated coronary artery.

Q: Can I receive cangrelor if I am already taking clopidogrel, prasugrel, or ticagrelor?
A: The decision is individualized, but if cangrelor is used in someone on chronic oral P2Y12 therapy, the timing of the last and next oral doses is carefully managed—clopidogrel and prasugrel are generally loaded immediately after stopping cangrelor, while ticagrelor can be given during or after the infusion—so your cardiology team will coordinate this.

Q: Is cangrelor safe during pregnancy or breastfeeding?
A: There are very limited data in pregnant or breastfeeding women, so cangrelor is used only when the potential benefit to the mother clearly outweighs potential risks, with the understanding that the drug’s very short half-life means any exposure of a fetus or nursing infant should be brief.

Q: How is cangrelor different from other blood thinners I might take at home?
A: Unlike oral antiplatelet or anticoagulant drugs used chronically, cangrelor is given only by IV in the hospital around the time of PCI, works within minutes, and wears off quickly, making it a tool for tight, short-term control of platelet activity during high-risk coronary procedures.